Back to top
more

Allakos (ALLK)

(Delayed Data from NSDQ)

$1.02 USD

1.02
162,387

-0.03 (-2.86%)

Updated Apr 24, 2024 04:00 PM ET

After-Market: $1.02 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (78 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Allakos (ALLK): Strong Industry, Solid Earnings Estimate Revisions

by Zacks Equity Research

Allakos (ALLK) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Biotech Stock Roundup: VRTX/CRSP Gene Therapy Label Expansion, ALLK Falls on Update

by Zacks Equity Research

Vertex (VRTX), CRSP and Allakos are in the spotlight on regulatory and pipeline updates.

Here's Why Allakos Inc. (ALLK) is Poised for a Turnaround After Losing -61.36% in 4 Weeks

by Zacks Equity Research

The heavy selling pressure might have exhausted for Allakos Inc. (ALLK) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Allakos (ALLK) Plummets 60% on Ending Development of Lead Drug

by Zacks Equity Research

Allakos (ALLK) decides to stop developing its lead drug after top-line data from two mid-stage studies did not achieve their primary endpoints.

Is Allakos (ALLK) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Allakos Inc. (ALLK) and McKesson (MCK) have performed compared to their sector so far this year.

Novavax (NVAX) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

Novavax (NVAX) is expected to provide updates on its ongoing clinical development in the first quarter of 2023.

Bellerophon (BLPH) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

Bellerophon (BLPH) is expected to provide updates on its proprietary INOpulse platform, being developed for treating several pulmonary hypertension indications, on its first-quarter earnings call.

Allakos Inc. (ALLK) Moves to Buy: Rationale Behind the Upgrade

by Zacks Equity Research

Allakos Inc. (ALLK) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Allakos Inc. (ALLK) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

Allakos Inc. (ALLK) closed at $3.86 in the latest trading session, marking a -1.03% move from the prior day.

Allakos Inc. (ALLK) Stock Moves -1.6%: What You Should Know

by Zacks Equity Research

Allakos Inc. (ALLK) closed the most recent trading day at $4.31, moving -1.6% from the previous trading session.

Allakos Inc. (ALLK) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

In the latest trading session, Allakos Inc. (ALLK) closed at $4.80, marking a -1.64% move from the previous day.

Allakos Inc. (ALLK) Gains As Market Dips: What You Should Know

by Zacks Equity Research

In the latest trading session, Allakos Inc. (ALLK) closed at $5.46, marking a +0.18% move from the previous day.

Allakos Inc. (ALLK) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

Allakos Inc. (ALLK) closed the most recent trading day at $5.69, moving -0.52% from the previous trading session.

Allakos Inc. (ALLK) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

Allakos Inc. (ALLK) closed at $5.97 in the latest trading session, marking a +1.7% move from the prior day.

Allakos Inc. (ALLK) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

Allakos Inc. (ALLK) closed at $5.08 in the latest trading session, marking a -0.39% move from the prior day.

Allakos Inc. (ALLK) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

Allakos Inc. (ALLK) closed the most recent trading day at $5.58, moving -0.18% from the previous trading session.

Allakos (ALLK) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

On Allakos' (ALLK) Q4 earnings call, investor focus is likely to be on updates on the progress of the company's lead pipeline candidate, lirentelimab.

Allakos Inc. (ALLK) Flat As Market Gains: What You Should Know

by Zacks Equity Research

Allakos Inc. (ALLK) closed at $6.54 in the latest trading session, marking no change from the prior day.

Allakos Inc. (ALLK) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

In the latest trading session, Allakos Inc. (ALLK) closed at $6.81, marking a -0.58% move from the previous day.

Down 86.1% in 4 Weeks, Here's Why Allakos Inc. (ALLK) Looks Ripe for a Turnaround

by Zacks Equity Research

Allakos Inc. (ALLK) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Has AbbVie (ABBV) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research

Here is how AbbVie (ABBV) and Allakos Inc. (ALLK) have performed compared to their sector so far this year.

Implied Volatility Surging for Allakos (ALLK) Stock Options

by Zacks Equity Research

Investors need to pay close attention to Allakos (ALLK) stock based on the movements in the options market lately.

Do Options Traders Know Something About Allakos (ALLK) Stock We Don't?

by Zacks Equity Research

Investors need to pay close attention to Allakos (ALLK) stock based on the movements in the options market lately.

Implied Volatility Surging for Allakos (ALLK) Stock Options

by Zacks Equity Research

Investors need to pay close attention to Allakos (ALLK) stock based on the movements in the options market lately.

Moving Average Crossover Alert: Allakos (ALLK)

by Zacks Equity Research

Allakos (ALLK) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front.